Enosi Therapeutics is a drug research and development company focused on providing industry-leading therapeutics for autoimmune diseases and cancer. The company was founded by world-renowned scientists Professor Sir Marc Feldmann, who discovered anti-tumor necrosis factor (anti-TNF) therapy as an effective treatment for rheumatoid arthritis and other autoimmune diseases ( Lasker Award, 2003 ); and Dr. H. Michael Shepard, whose research in humanized antibodies created the first monoclonal antibody therapy targeting cancer oncogene encoded-proteins ( Lasker award, 2019). Enosi Therapeutics combines Feldmann and Shepard’s expertise in cancer and autoimmune diseases with Executive Chairman Dr. James N. Woody’s unique combination of medical, scientific and management expertise to expand therapeutic options. To learn more about Enosi Therapeutics, visit www.enositherapeutics.com.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 590 Pearl Street,
- Industry
- Health, Wellness & Fitness
- Website
- https://enositherapeutics.com
- Keywords
- Toronto.
- HQ
- Eugene, Oregon
Enosi Therapeutics Questions
Enosi Therapeutics's website is https://enositherapeutics.com
Enosi Therapeutics's LinkedIn profile is https://www.linkedin.com/company/enositherapeutics
Enosi Therapeutics has
1 employees.
View email and phone details for 1
employees at Enosi Therapeutics.
Enosi Therapeutics's industry is
Health, Wellness & Fitness
Enosi Therapeutics's top competitors are
Susan B Silverman Consulting,
Sedia Biosciences Corp.,
Echelon Wealth Partners,
Niagen Bioscience,
Enosis Therapeutics,
X2 Games,
Bend Bioscience,
Pdx Pharmaceuticals,
Veana Therapeutics, Llc.,
Unify Pharmaceuticals.
Enosi Therapeutics's categories are Health, Wellness & Fitness
Enosi Therapeutics's founding year is 2020
